These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 12138991)

  • 1. Successful treatment of a large macroprolactinoma with cabergoline during pregnancy.
    Liu C; Tyrrell JB
    Pituitary; 2001 Aug; 4(3):179-85. PubMed ID: 12138991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
    Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
    Colao A; Di Sarno A; Landi ML; Scavuzzo F; Cappabianca P; Pivonello R; Volpe R; Di Salle F; Cirillo S; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabergoline therapy for macroprolactinoma during pregnancy: a case report.
    Shahzad H; Sheikh A; Sheikh L
    BMC Res Notes; 2012 Oct; 5():606. PubMed ID: 23110890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
    Delgrange E; Maiter D; Donckier J
    Eur J Endocrinol; 1996 Apr; 134(4):454-6. PubMed ID: 8640297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.
    Howell DL; Wasilewski K; Mazewski CM; Hudgins RJ; Meacham LR
    J Pediatr Hematol Oncol; 2005 Jun; 27(6):326-9. PubMed ID: 15956887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of macroprolactinoma with cabergoline during pregnancy].
    Forsbach-Sánchez G; Tamez-Pérez HE; Hernández-Herrera R; Bafidis-Lechuga B
    Rev Med Inst Mex Seguro Soc; 2009; 47(3):307-10. PubMed ID: 20141661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabergoline treatment in a case of macroprolactinoma after delivery.
    Falsetti L
    Acta Eur Fertil; 1995; 26(3):105-7. PubMed ID: 9098469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T; Arikan E; Tasan E; Hatemi H
    Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.
    Cannavò S; Curtò L; Squadrito S; Almoto B; Vieni A; Trimarchi F
    J Endocrinol Invest; 1999 May; 22(5):354-9. PubMed ID: 10401709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolactinomas and pregnancy.
    Bronstein MD
    Pituitary; 2005; 8(1):31-8. PubMed ID: 16411066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature.
    Berwaerts J; Verhelst J; Abs R; Appel B; Mahler C
    J Endocrinol Invest; 2000 Jun; 23(6):393-8. PubMed ID: 10908167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
    Iyer P; Molitch ME
    Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
    Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactin-secreting tumors, dopamine agonists and pregnancy: a longitudinal experience of a tertiary neuroendocrine center.
    Prencipe N; Bona C; Cuboni D; Berton AM; Bioletto F; Varaldo E; Aversa LS; Sibilla M; Gasco V; Ghigo E; Grottoli S
    Pituitary; 2024 Jun; 27(3):269-276. PubMed ID: 38499816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy.
    Rastogi A; Bhadada SK; Bhansali A
    Gynecol Endocrinol; 2017 Apr; 33(4):270-273. PubMed ID: 27908214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.